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Where Are We Now?
I
n the current study, Collier and
colleagues [5] describe an in-vitro
drug-screening approach to evalu-
ate micrometastatic disease in osteo-
sarcoma. They generated sarcospheres
using established human osteosarcoma
cell lines with metastatic potential and
found an individual response upon
methotrexate, doxorubicin, and cis-
platin (MAP) treatment.
There is a desperate need to im-
prove treatment strategies in patients
with metastatic osteosarcoma. Five-
year event-free survival of patients
with localized osteosarcoma is ap-
proximately 70%, but that number
drops to around 20% for those with
metastatic disease. For this reason, the
work of Collier and colleagues is
important.
A conventional drug-
development path requiring drugs to
induce regression of established
lesions has not led to improvements
of survival during the last 30 years.
Because metastasis is often fatal, it is
essential that we focus on developing
therapeutics that target metastatic
progression [12]. To do so, we
heavily depend on cancer modeling,
although all models have limitations
and are imperfect representations of
real systems [21]. Drug screeening
using commercially available cell
lines is hampered by considerable
genomic instability during cell cul-
ture due to gene expression and
chromosomal abberrations [14]. By
allowing the interaction of
osteosarcoma cells and extracellular
matrix, three-dimensional (3-D) in
vitro models offer a clear advantage
over 2-D models. This interaction
regulates the proliferation and dif-
ferentiation in space and time, and
helps identify the role of proteins
involved in the metastatic behavior
[19]. In vivo sarcoma models are di-
vided into spontaenous models (for
example, dogs that develop osteo-
sarcomas) and induced models (such
as syngenic mouse models). Syn-
genic mouse models are distin-
guished from xenografts, whereby
the specific inoculation of patient-
derived tumor material is referred as
patient-derived xenografts. Such
models, each with its limitations,
have been refined over the years and
have good predictive value [15, 16].
But because of a general lack of
changes to survivorship over time in
patients with osteosarcoma despite
these laboratory efforts, clincial trials
are absolutely instrumental and have
to be supported for patients with os-
teosarcoma [10]. On the other hand,
stringent inclusion criteria cannot be
emphasized enough, and differences
in these criteria may explain the fact
that survival of patients with local-
ized osteosarcoma has not improved
in the last three decades [11].
Therefore, 3-D sarcospheres focus-
ing on the metastatic cascade using
patient-derived tumor material will
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be a necessary step to define new
targets.
Where Do We Need To Go?
In this context, a rational progression
from preclinical studies using in-vitro
cell lines in combination with in vivo
mouse/dog model approaches must be
developed. As Collier and colleagues
noted in their study, the establishment
of in vitro 3-D cellular cultures of tu-
mor cells (known as organoids) may
represent the basis for high-throughput
drug screening to identify molecules
that limit cancer-cell growth. Such
a drug would then be used in patient-
derived xenograft models to generate
possible treatment options, before be-
ing used as a tumor precision approach
in clinical trials [7].
The goal is to improve the survival
of patients with osteogenic sarcoma
using a personalized drug approach.
Collier and colleagues [5] focused on
metastasis and noted that sarcospheres
are just a starting point, and several
challenging issues still need to be con-
fronted. First, to develop drug combi-
nations against metastases, we will
likely need to target several steps of the
process that lead to metastases, in-
cluding genetic mutations and protein
expression. But the problem goes well
beyond those elements, and so we need
also to focus attention on epigenetic
factors, metabolic abnormalities, the
immunolgy of cancer, the micro-
environments in which tumors reside,
and how tumor cells enter the blood-
stream [18]. It is unlikely that a singular
genetic alteration (such as in gastroin-
testinal stromal tumor) can be success-
fully targeted, and combinations of
several targets have to be envisaged,
adding a tremendous complexity to
define treatment success.
Second, next-generation sequencing
by delineating the genomic landscape of
individual tumors will greatly impact
the future of cancer therapy. But this
kind of research is challenging. For
example, each sequence analysis cap-
tures only one moment in time, while
cancer is continuously evolving and
adapting [21], which helps explain the
recently recognized intratumoral het-
erogeneity [8, 20], as well as the need
for novel drug therapies [4]. If multiple
biopsies of one single tumor share only
one-third of all mutations being present
in the respective tumor [8], one might
question how representative an ex-vivo
analysis for drug screening may be.
This is particularly important for
patients with osteosarcoma, where the
biopsy to establish the diagnosis is fol-
lowed by neoadjuvant chemotherapy,
before complete surgical resection.
Finally, based on the action of new
anticancer agents with greater molec-
ular specificity, we may have to in-
troduce new rules for developing drug
combinations. Instead of additive or
synergistic treatment responses, drug
combinations may be effective via in-
dependent activities of the individually
administered drugs. Therefore, a better
understanding of signaling networks is
imperative for combination regimens
[17]. Further, a treatment response is
usually assessed by progression free
survival and/or tumor necrosis rate.
Considering the dynamics of cancer
therapies, the kill rate and progression-
free survival are not sufficient meas-
ures for long-term cancer control;
instead, time to tumor regrowth may be
more accurate [3].
How Do We Get There?
Most oncology drugs come onto the
market without clear evidence that they
improve overall survival or a patient’s
quality of life. And if a benefit is shown,
then it’s not always meaningful [6]. Ap-
plying stringent criteria with robust pre-
clinical evidence before performing
clinical trials is absolutely necessary [11].
Because metastasis is the primary
cause of death, the effectiveness of any
therapy can only be measured by the
ability to interfere with this event.
Metastatic tumor cells (or circulating
tumor cells), which can be collected
from the peripheral blood, allow for the
early detection of tumor status, which
is the key. Circulating tumor cells from
liquid biopsies—through the analysis
of the unique cancer cells’ protein or
oncogenic mutations and epigenetic
changes—allow for the assessment of
genetic evolution to adapt to any
treatment [1, 13]. Further, identifying
protein biomarker signatures from the
blood may, simultaneously allow pre-
cision diagnostics to detect the disease
as early as possible [2].
Should these approaches generate
a wealth of data, international and in-
terdisciplinary collaboration of nu-
merous groups would be needed. The
development of the High Dimensional
Data platform—a relational biologic
database derived from matched osteo-
sarcoma biospecimens in which di-
verse experimental readouts were
generated and digitally deposited
[9]—promotes in silico hypothesis
testing in sarcoma biology, and may
represent an invaluable step forward to
improve the overall survival of patients
with osteosarcoma.
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